CROI 2015 Program and Abstracts

Oral Sessions

ORAL SESSIONS

MONDAY, FEBRUARY 23, 2015

Session MD Presentation

Room 6E

Monday, February 23, 2015 • Oral Sessions

1:00 pm– 2:00 pm Martin Delaney Presentation: How to End the HIV Epidemic: Community Perspectives 6 Martin Delaney Presentation: How to End the HIV Epidemic: Community Perspectives Moderator Steven F. Wakefield , HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, US Panelists Connie Celum , University of Washington, Seattle, WA, US Damon L. Jacobs , Private Practice Psychotherapist, Brooklyn, NY, US Matthew V. Sharp , Shanti Project, Berkeley, CA, US 2:30 pm– 4:30 pm Clinical Trial Design and Analysis Target audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical trial results. Level of knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical studies. Objectives: At the completion of the session, participants will be able to: • Describe strategies for evaluating the effectiveness of interventions. • Interpret adherence measures. • Evaluate study design with infrequent endpoints. Workshop Conveners Susan P. Buchbinder , San Francisco Department of Public Health, San Francisco, CA, US Richard E. Chaisson , The Johns Hopkins University, Baltimore, MD, US 7 Getting SMART About Innovative Designs for Studying Effectiveness: The Case of Adaptive Implementation SessionW2Workshop

SessionW1Workshop

Room 6E

9:00 am– 12:30 pm Program CommitteeWorkshop for New Investigators and Trainees Target audience: This workshop is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic). Level of knowledge: It is assumed that participants have been conducting active research in the field for less than 3 years. Objectives: At the completion of the session, participants will be able to: • Describe the major areas of HIV investigation being presented at the conference. • Identify the top 3 to 5 research questions in the field of retroviruses and opportunistic infections today. • Describe some of the proposed solutions for addressing the challenges presented globally by a variety of retroviruses and opportunistic infections. Workshop Conveners Scott M. Hammer , Columbia University Medical Center/New York- Presbyterian Hospital, New York, NY, US John W. Mellors , University of Pittsburgh, Pittsburgh, PA, US 1 A Path to an HIV Vaccine Galit Alter Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, US 2 Animal Models of HIV Prevention and Cure Guido Silvestri Emory University, Decatur, GA, US 3 HIV Prevention 2.0: What’s Next? Susan P. Buchbinder San Francisco Department of Public Health, San Francisco, CA, US 4 Pathogenesis of HIV Complications Peter W. Hunt University of California San Francisco, San Francisco, CA, US 5 HIV Cure Research John M. Coffin Tufts University, Boston, MA, US

Room 6E

Interventions Daniel Almirall University of Michigan, Ann Arbor, MI, US

8

The Clinical Pharmacology of Medication Adherence Terrence Blaschke Stanford University, Stanford, CA, US Epidemiological and Biostatistical Issues in Studying Rare Events in HIV Stephen J. Gange Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US

9

1

CROI 2015